SHORT COMMUNICATION

Down-regulation of ER-α36 mRNA in serum exosomes of the patients with hepatocellular carcinoma

Hui Huang1 | Zhiyuan Zhou2 | Hongyan Li2 | Yong Zhang1 | Liang Zhao1 | Zhidong Wang1 | Qiqi Zhang1 | Chunyan Liu1 | Changxin Han1 | Qi Wang2 | Chunwen Pu1 | Wei Zou2

1Department of Biobank, The Affiliated Sixth People’s Hospital of Dalian Medical University, Dalian, China
2College of Life Science, Liaoning Normal University, Dalian, China

Correspondence
Chunwen Pu, Department of Biobank, The Affiliated Sixth People’s Hospital of Dalian Medical University, No. 269, Guibai Road, Ganjingzi District, Dalian 116001, China.
Email: 2295050337@qq.com

Funding information
Health Commission of Dalian Foundation, Grant/Award Number: [2016] No. 111; Natural Science Foundation of Liaoning Province, Grant/Award Number: 20170540209

Epidemiological data indicated that the incidence and mortality of hepatocellular carcinoma (HCC) in males are higher than that in females.1 In 2018, the ratio of the number of cases to deaths in men and women was about 2.5:1 and 2.3:1, respectively. However, the incidence of HCC in postmenopausal women is significantly higher, which is almost equal to the incidence of men,2 suggesting that the estrogen-signaling pathways play a vital role in development of HCC. The estrogen receptor alpha 66 (ER-α66), commonly used as a breast cancer marker, is a well-known mitogenic nuclear receptor.3 It has been reported that ER-α66 is involved in the development of HCC.4 However, the role of ER-α66 in the diagnosis of HCC is uncertain. The estrogen receptor alpha 36 (ER-α36) is a novel estrogen receptor variant discovered by Wang et al in 2005.5 Studies have shown that ER-α36 mediates the non-genomic effects of estrogen and participates in the progress of different cancers through MAPK/ERK, PI3K/Akt, and other signaling pathways.6,7 Studies have also shown that the signal-regulating loop formed by ER-α36 and EGFR can affect the proliferation of HCC,8 but its role in the diagnosis of HCC has not been reported before.

In recent years, exosomes have attracted widespread attention as a new pathway for intercellular communication. Exosomes are membrane-like vesicle structures with a diameter of 30-150 nm.9 Almost all cells in the human body release exosomes under physiological conditions, and tumor cells are a generous producer of exosomes that carry a variety of genetic and molecular cargoes that reflect the parental cells. A large number of studies have shown that tumor-derived exosomes play an important role in tumor proliferation, invasion, metastasis, angiogenesis, and drug resistance.10,11 In addition, bioactive molecules in exosomes can be used for the diagnosis and prognosis of cancer.12,13 However, the clinical significance of estrogen and its receptor in HCC exosomes is unknown. Our previous study has found that the combined examination of extracellular miR-21 and miR-144 in serum is helpful in diagnosing HCC,14 suggesting that extracellular vesicles or exosomes may provide novel approaches for the diagnosis and prognosis of HCC.
Thus, we decided to examine the expression of estrogen and its receptor variants, ER-α66 and ER-α36, in HCC tissue and blood samples. Here, we report our study on the expression pattern of estrogen and its receptor variants in serum exosomes of HCC, and provide insightful information for the diagnosis of human HCC.

Two hundred and thirty people meeting the experimental criteria were recruited from January 2015 to January 2018 at the Affiliated Sixth People’s Hospital of Dalian Medical University. The people were categorized in the following four categories: normal, chronic liver disease (CHB), liver cirrhosis (LC), and hepatocellular carcinoma (HCC). CHB, LC, and HCC were all diagnosed according to the standards of the Asian Pacific Association for the Study of the Liver, and normal category was a healthy donor with no-disease detected. The study was approved by the ethics committee of the Affiliated Sixth People’s Hospital of Dalian Medical University (2016-013-007). The tissue and blood samples used in the study were obtained with the patient’s informed consent.

**TABLE 1** Patient cohort description of 17β-estradiol

| Clinical parameter | CHB (n = 55) | LC (n = 56) | HCC (n = 56) |
|--------------------|--------------|-------------|--------------|
| Age (years)        | <60          | 51          | 43           | 37           |
|                    | ≥60          | 4           | 13           | 19           |
| Gender             | Male         | 55          | 56           | 56           |
|                    | Female       | 0           | 0            | 0            |
| HBsAg              | Positive     | 55          | 49           | 40           |
|                    | Negative     | 0           | 5            | 1            |
| AFP (ng/mL)        | <400         | 52          | 54           | 35           |
|                    | ≥400         | 1           | 0            | 17           |
| ALT (U/L)          | 162.27 ± 205.36 | 53.77 ± 76.59 | 55.28 ± 53.93 |
First, the surgically resected HCC tissue and its adjacent normal tissue were selected for IF staining (primary antibody: ER-α66, 1:400, CST, 13258; ER-α36, 1:300; fluorescence-conjugated secondary antibody: 1:400, Jackson, 111-165-003, and 115-605-003). The results showed that ER-α66 and ER-α36 were expressed in both HCC and adjacent normal tissue, and located in the cytoplasm and cell membrane of hepatocytes and HCC cells (Figure 1A). Second, the levels of E2 in plasma from the patients with CHB, LC, and HCC were examined to determine the changes of E2 in blood during the process of CHB developing into HCC (patient clinical data in Table 1) with the Access Estradiol Kit (Beckman Coulter, 33540). In order to avoid the female cyclical changes affect estrogen levels in blood, only male patients were recruited in this experiment. Results showed that plasma estrogen levels were found to be significantly down-regulated in HCC compared with adjacent tissue, and significantly lower in the HCC patients compared with the LC patients (P < .05) (Figure 1B), suggesting that estrogen may be involved in the regulation of the development of HCC.

Second, we detected the expression patterns of ER-α66 and ER-α36 using IHC kit (Universal Two-Step IHC Kit, ZSGB-BIO, PV-9000) with antibodies against ER-α66, 1:100, Abcam, ab3575 and ER-α36, 1:100, and Western blot with antibodies for ER-α36 using Western blot analysis. Western blot results showed that ER-α36 was present at the lowest level in the exosome from normal and at the highest from CHB group (Figure 3B), and the qRT-PCR results showed that the mRNA expression of ER-α36 was significantly down-regulated in HCC group (P < .01) compared to CHB group, consistent with the trend found in the Western blot results (Figure 3C). The ROC curve showed that the ER-α36 mRNA in the exosome could effectively distinguish the patients with CHB and HCC (AUC = 0.828, P = .005, 95% CI 0.675-0.980, Figure 3D), suggesting that ER-α36 mRNA in serum exosomes potentially has a role in HCC diagnosis.

Finally, the expression of two variants of ER-α in HCC and adjacent tissue was further examined at mRNA level. Tissue mRNA was extracted with miRcute miRNA Isolation Kit, (TANGEN, DP501); reverse transcribed (FastKing RT Kit, TIANGEN, KR116) and examined with qRT-PCR assay (SuperReal PreMix Plus, TIANGEN, FP205, the primer sequences are included in the Supporting Information Table). The mRNA levels agreed well with the protein levels. Compared with adjacent tissue, the mRNA levels of ER-α66 (P < .001, Figure 2G) and ER-α36 (P < .05, Figure 2H) were significantly down-regulated in HCC tissue. In addition, the ROC curve was used to analyze the possibility of using two ER-α mRNAs for the diagnosis of HCC. The results showed the area under the curve (AUC) of ER-α66 mRNA was 0.876 (P = .003, 95% CI = 0.732-1.000) and that of ER-α36 mRNA was 0.842 (P = .002, 95% CI 0.669-1.000), indicating that mRNAs of ER-α66 and ER-α36 show good accuracy for the diagnostic of HCC and could be effectively used to distinguish HCC from adjacent tissue (Figure 2I).

In further experiments, exosomes in serum of the patients with HCC were isolated and identified using Exo-spin Exosome Purification Kit (Cell Guidance Systems, EX02) to examine the expression pattern and clinical significance of ER-α36 in exosomes. Transmission electron microscopy and nano-particle size concentration analysis (ZetaView PMX 110, Particle Metrix, Meerbusch, Germany; software: ZetaView 8.04.02) showed that the obtained samples were concentrated in the diameter between 30 and 150 nm, and the concentration was above 3 x 10^6, which agrees well with exosome characteristics (Figure 3A). In addition, serum exosomes from normal, and the patients with CHB and HCC were collected, and then ER-α36 expression was examined using Western blot analysis. Western blot results showed that ER-α36 was present at the lowest level in the exosome from normal patients and at the highest from CHB group (Figure 3B), and the qRT-PCR results showed that the mRNA expression of ER-α36 was significantly down-regulated in HCC group (P < .01) compared to CHB group, consistent with the trend found in the Western blot results (Figure 3C). The ROC curve showed that the ER-α36 mRNA in the exosome could effectively distinguish the patients with CHB and HCC (AUC = 0.828, P = .005, 95% CI 0.675-0.980, Figure 3D), suggesting that ER-α36 mRNA in serum exosomes potentially has a role in HCC diagnosis.

Estrogen and its receptors are involved in the development and progression of breast cancer, but their expression pattern and clinical significance in the serum exosomes of HCC are not known. There is evidence indicating that estrogen may be a protective factor against the progression of liver cancer in the patients with HBV infection. In this paper, we found that...
FIGURE 2  ER-α66 and ER-α36 were both down-regulated in hepatocellular carcinoma (HCC) tissue. A, IHC staining of ER-α66 and ER-α36 proteins in HCC and adjacent tissues; ER-α66 and ER-α36 were mainly located in the cytoplasm and cell membrane (×400). B and C, Quantification of IHC results for ER-α66 (adjacent: 3.62 ± 7.57 and tumor: 0.74 ± 2.12, n = 26) and ER-α36 (adjacent: 6.69 ± 6.75 and tumor: 5.94 ± 5.73, n = 10). D, Western blot of ER-α66 and ER-α36 in HCC and adjacent tissues. E and F, Quantification of Western blot results for ER-α66 (adjacent: 0.53 ± 0.33 and tumor: 0.60 ± 0.47, n = 6) and ER-α36 (adjacent: 1.27 ± 0.40 and tumor: 1.16 ± 0.30, n = 6). G and H, qRT-PCR results of ER-α66 mRNA (adjacent: 0.0026 ± 0.0033 and tumor: 0.0003 ± 0.0003, n = 11) and ER-α36 mRNA (adjacent: 0.4700 ± 0.3180 and tumor: 0.3058 ± 0.9045, n = 14) with *P < .05 and **P < .01, respectively. I, Efficiency of ER-α66 and ER-α36 mRNA in the diagnosis of HCC: (a) ROC curves of ER-α66 mRNA; (b) ROC curves of ER-α36 mRNA.

the plasma estrogen levels were significantly elevated in the LC patients compared with that in the CHB patients, and significantly lower in the HCC patients compared with the LC patients. Serin et al reported that liver estrogen inactivation capacity in the patients with cirrhosis is weakened, leading to an increase in blood estrogen levels. This finding is consistent with our results, suggesting that estrogen may be involved in the development of HCC.

ER-α (ESR1) and ER-β (ESR2) are two major subtypes of estrogen receptor. Changes in the structure and content of
Figure 3  ER-α36 mRNA was significantly down-regulated in the exosome from the HCC patients. A, Identification and characterization of serum exosomes from the patients with HCC: (a) Transmission electron micrograph of purified exosome (30-110 nm in diameter; bars 100 nm; arrow indicates exosome); (b) Morphology of exosome using ZetaView; (c) Particle size and distribution of exosome using ZetaView. B, Western blot quantification of ER-α36 in the serum exosomes from the normal subjects (0.80 ± 0.28, n = 6), and the patients with CHB (0.90 ± 0.64, n = 6) and HCC (0.85 ± 0.66, n = 6). C, qRT-PCR result of ER-α36 in the serum exosomes from the normal subjects (3.09 ± 3.18, n = 11), and the patients with CHB (7.84 ± 4.23, n = 10) and HCC (3.79 ± 2.86, n = 18) (**P < .01). D, ROC curve analysis of ER-α36 mRNA in the exosomes from the patients with CHB and HCC.

these two subtypes will eventually lead to changes in the physiological functions of estrogen. Most of the biological effects of estrogen in the liver are mediated by ER-α. Abnormal expression of ER-α in the liver is associated with hepatocyte proliferation, which may induce or promote liver diseases. Furthermore, in the early stages of CHB, the variants of ER-α are highly expressed in male patients compared with female patients, and are overexpressed in tumor tissues compared with normal tissues. Therefore, the variants of ER-α may have diagnostic value in liver cancer.

ER-α66 is the classical estrogen receptor that mediates the genomic effects of estrogen. At present, ER-α66 has been widely used as a marker for the diagnosis and treatment of breast cancer, but its diagnostic value in HCC is unknown. In this study, we found that ER-α66 expression in most HCC tissue was lower than that of the adjacent tissue, and the ROC curve showed that ER-α66 mRNA had a good diagnostic value in HCC. Miceli et al found that ER-α66 is highly expressed in normal liver tissue, but is almost absent in HCC tissue, consistent with our results. Meanwhile, Wang et al reported that both mRNA and protein levels of ER-α66 were downregulated in HCC HepG2 cells (P < .01), and the ER-α66 mRNA levels in the tumor tissue were up-regulated compared with the non-cancerous tissues (P < .05). In fact, we also observed an up-regulation of ER-α66 in a small subset of HCC samples, the underlying mechanism of which requires further research.

ER-α36 is a novel variant of ER-α66 discovered by Wang et al in 2005. Previous studies have found that high ER-α36 expression is often accompanied by a high degree of malignancy and poor prognosis of cancer, indicating that ER-α36 plays an important role in tumor progression. Studies have shown that ER-α36 is upregulated in HCC tissue and is more expressed in primary liver cancer than in secondary
liver cancer. In this study, we found that ER-α36 expression in the HCC tissues from most patients was lower than that of the adjacent tissues, and the ROC curve showed that ER-α36 mRNA in cancer tissues has diagnostic value in HCC. However, ER-α36 expression in a small portion of liver cancer samples was found increased compared to adjacent tissues, the exact reason of which requires further investigation.

Exosomes are carriers of biologically active substances, and are ideal materials for liquid biopsy. However, there are few reports that described mRNA in exosomes for the diagnosis of human HCC. In this study, we discovered that ER-α36 was present in the exosome of the patients with HCC and ER-α36 mRNA was significantly downregulated in exosome from HCC patients. In addition, the ROC curve showed that ER-α36 mRNA in exosomes could effectively distinguish the patients with CHB and HCC, suggesting that ER-α36 mRNA may serve as a good diagnostic biomarker for HCC. However, we barely detected ER-α66 mRNA in the exosomes (data not shown). The exact reason for the low abundance of ER-α66 in the exosomes from HCC patients needs to be further investigated.

In summary, ER-α36 mRNA in the exosomes from HCC patients was significantly downregulated, indicating a possibility of using ER-α36 mRNA in serum exosomes as a good diagnostic biomarker for HCC.

ACKNOWLEDGMENTS
This work was supported by Liaoning Provincial Natural Science Foundation (20170540209) and Health Commission of Dalian Foundation ([2016] No. 111). The authors are grateful to Dr Zhaoyi Wang from Beijing Shenogen Pharma Group to providing anti-ER-α36 antibody and Dr Wei Duan from School of Medicine, Deakin University for her valuable input to improve our manuscript.

FUNDING INFORMATION
Liaoning Provincial Natural Science Foundation, Grant number: 20170540209; Health Commission of Dalian Foundation, Grant number: [2016] No. 111

CONFLICT OF INTEREST
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

AUTHOR CONTRIBUTIONS
Study concept and design: C.P. and W.Z. Data acquisition: Z.Z. Data analysis and interpretation: Y.Z., L.Z., Z.W., and C.L. Draft of the manuscript: H.H. Critical revision of the manuscript for important intellectual content: H.H., C.P., and W.Z. Statistical analysis: H.L., C.H., Q.Z., and Q.W. All authors participated in the revision and agreed with the final manuscript.

DATA ACCESSIBILITY
Technical appendix, statistical code, and dataset are available from the corresponding authors. Participants gave informed consent for data sharing.

ORCID
Hui Huang https://orcid.org/0000-0001-9901-8953

REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
2. Li Y, Xu A, Jia S, et al. Recent advances in the molecular mechanism of sex disparity in hepatocellular carcinoma. Oncol Lett. 2019;17:4222-4228.
3. Jameera Begam A, Jubie S, Nanjan MJ. Estrogen receptor agonists/antagonists in breast cancer therapy: a critical review. Bioorg Chem. 2017;71:257-274.
4. Hishida M, Nomoto S, Inokawa Y, et al. Estrogen receptor 1 gene as a tumor suppressor gene in hepatocellular carcinoma detected by triple-combination array analysis. Int J Oncol. 2013;43:88-94.
5. Wang Z, Zhang X, Shen P, et al. Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem Biophys Res Commun. 2005;336:1023-1027.
6. Zhang XT, Kang LG, Ding L, et al. A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene. 2011;30:770-780.
7. Sun L, Wang J, Zhang L, et al. Expression of ER-α36, a novel variant of estrogen receptor in endometrial carcinoma and its clinical significance. Gynecol Obstet Invest. 2013;75:68-72.
8. Shi L, Dong B, Li Z, et al. Expression of ER-[alpha]36, a novel variant of estrogen receptor [alpha], and resistance to tamoxifen treatment in breast cancer. J Clin Oncol. 2009;27:3423-3429.
9. Hessvik NP, Llorente A. Current knowledge on exosome biogenesis and release. Cell Mol Life Sci. 2018;75:193-208.
10. Xue X, Wang X, Zhao Y, et al. Exosomal miR-93 promotes proliferation and invasion in hepatocellular carcinoma by directly inhibiting TIMP2/TP53INP1/CDKN1A. Biochem Biophys Res Commun. 2018;502:515-521.
11. Fang JH, Zhang ZL, Shang LR, et al. Hepatoma cell-secreted exosomal microRNA-103 increases vascular permeability and promotes metastasis by targeting junction proteins. Hepatology. 2018;68:1459-1475.
12. Li W, Li C, Zhou T, et al. Role of exosomal proteins in cancer diagnosis. Mol Cancer. 2017;16:145. <https://bib>.
13. Jiang N, Pan J, Fang S, et al. Liquid biopsy: circulating exosomal long noncoding RNAs in cancer. Clin Chim Acta. 2019;495:331-337.
14. Pu C, Huang H, Wang Z, et al. Extracellular vesicle-associated mir-21 and mir-144 are markedly elevated in serum of patients with hepatocellular carcinoma. Front Physiol. 2018;9:930.
15. Shimizu I, Ito S. Protection of estrogens against the progression of chronic liver disease. Hepatol Res. 2007;37:239-247.
16. Serin A, Akarsu M, Akpinar H, et al. Changes of some hormones levels in patients with hepatitis B virus-related chronic liver disease. Gastroenterology Res. 2013;6:134-138.
17. Ahlborg-Dieker DL, Stride BD, Leder G, et al. DNA binding by estrogen receptor-alpha is essential for the transcriptional response to estrogen in the liver and the uterus. *Mol Endocrinol*. 2009;23:1544-1555.

18. Giannitrapani L, Soresi M, La Spada E, et al. Sex hormones and risk of liver tumor. *Ann NY Acad Sci*. 2006;1089:228-236.

19. Villa E, Camellini L, Dugani A, et al. Variant estrogen receptor messenger RNA species detected in human primary hepatocellular carcinoma. *Cancer Res*. 1995;55:498-500.

20. Villa E, Dugani A, Moles A, et al. Variant liver estrogen receptor transcripts already occur at an early stage of chronic liver disease. *Hepatology*. 1998;27:983-988.

21. Miceli V, Cocciadiferro L, Fregapane M, et al. Expression of wild-type and variant estrogen receptor alpha in liver carcinogenesis and tumor progression. *OMICS*. 2011;15:313-317.

22. Wang CJ, Guo DK, You TG, et al. Inhibition of hepatocellular carcinoma by fulvestrant involves the estrogen receptor α and Wnt pathways in vitro and in patients. *Mol Med Rep*. 2014;10:3125-3131.

23. Zhang J, Ren J, Wei J, et al. Alternative splicing of estrogen receptor alpha in hepatocellular carcinoma. *BMC Cancer*. 2016;16:926.

**SUPPORTING INFORMATION**
Additional supporting information may be found online in the Supporting Information section at the end of the article.